Serum ADAMTS18 Levels at Admission Are Associated With 3-Month Functional Outcome After Acute Ischemic Stroke
Abstract
AIMS: ADAMTS18 is a secreted metalloproteinase implicated in vascular homeostasis and protection against ischemic brain injury. However, its clinical relevance in acute ischemic stroke (AIS) remains unclear. METHODS: We retrospectively analyzed 194 AIS patients from the Chengdu Stroke Registry. Serum ADAMTS18 levels were measured within 48 hours of admission using ELISA. Associations between ADAMTS18 levels and 3-month poor outcomes (modified Rankin Scale score 3-6) were evaluated using logistic regression. Predictive performance was assessed using area under the receiver operating characteristic curve (AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). RESULTS: <0.001). Incorporating ADAMTS18 into predictive models improved discrimination (AUC = 0.91 vs. 0.86, P = 0.011), IDI (11.14%, P<0.001), and NRI (77.1%, P<0.001). CONCLUSION: Lower admission ADAMTS18 levels are independently associated with poor 3-month functional outcomes after AIS and may provide additional prognostic information.
Related
- Early hematoma expansion provides incremental prognostic information beyond admission characteristics for 6-month functional outcome after adult traumatic brain injury
- Factors associated with subtype classification and 3-month functional outcome in ischemic stroke, focusing on large-artery atherosclerosis and small-vessel occlusion : A retrospective observational study
- Early prediction of 3-month functional outcome after acute ischemic stroke: an explainable model based on routine clinical data
- Admission TRIAGES score for unfavorable functional outcome after traumatic brain injury: association, prognostic performance, and comparison with the Glasgow coma scale
- The admission neutrophil-to-lymphocyte ratio improves early prediction of poor functional outcome beyond the modified Rankin Scale in viral encephalitis: a cohort study
BibTeX
@article{cui2026serum,
title = {{Serum ADAMTS18 Levels at Admission Are Associated With 3-Month Functional Outcome After Acute Ischemic Stroke}},
author = {Ting Cui and Huan Wang and Yuyi Zhu and Mingxi Chen and Yaqi Chen and Keying Wu and Junfeng Liu and Zilong Hao and Bo Wu and Deren Wang},
journal = {Journal of Atherosclerosis and Thrombosis},
year = {2026},
month = oct,
doi = {10.5551/jat.66202},
url = {https://www.jstage.jst.go.jp/article/jat/33/10/33_66202/_article},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Serum ADAMTS18 Levels at Admission Are Associated With 3-Month Functional Outcome After Acute Ischemic Stroke
AU - Ting Cui
AU - Huan Wang
AU - Yuyi Zhu
AU - Mingxi Chen
AU - Yaqi Chen
AU - Keying Wu
AU - Junfeng Liu
AU - Zilong Hao
AU - Bo Wu
AU - Deren Wang
PY - 2026
DA - 2026/10/01
JO - Journal of Atherosclerosis and Thrombosis
DO - 10.5551/jat.66202
UR - https://www.jstage.jst.go.jp/article/jat/33/10/33_66202/_article
AB - AIMS: ADAMTS18 is a secreted metalloproteinase implicated in vascular homeostasis and protection against ischemic brain injury. However, its clinical relevance in acute ischemic stroke (AIS) remains unclear. METHODS: We retrospectively analyzed 194 AIS patients from the Chengdu Stroke Registry. Serum ADAMTS18 levels were measured within 48 hours of admission using ELISA. Associations between ADAMTS18 levels and 3-month poor outcomes (modified Rankin Scale score 3-6) were evaluated using logistic regression. Predictive performance was assessed using area under the receiver operating characteristic curve (AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). RESULTS: <0.001). Incorporating ADAMTS18 into predictive models improved discrimination (AUC = 0.91 vs. 0.86, P = 0.011), IDI (11.14%, P<0.001), and NRI (77.1%, P<0.001). CONCLUSION: Lower admission ADAMTS18 levels are independently associated with poor 3-month functional outcomes after AIS and may provide additional prognostic information.
SN - 1880-3873
SN - 1340-3478
ER -